Emergence of melioidosis in Brazil: a case series

Abstract

Background

Melioidosis is a serious disease caused by the bacterium Burkholderia pseudomallei which affects humans and animals. It results in a wide spectrum of clinical manifestations, mainly in the respiratory tract, progressing to septic shock and death.

Case presentation

Herein, we present a series of seven patients (median age: 41 years) with confirmed melioidosis, treated at a public hospital in Piauí State, Brazil between 2019 and 2021. The most common clinical presentations were fever, cough, pneumonia, and abdominal pain. The mean duration of antibacterial therapy with 1 g of meropenem was 28.6 ± 1.1 days. Six patients recovered and one died. The mean hospitalization time was 51.0 ± 39.2 days.

Conclusions

Melioidosis is an emerging infectious disease in Brazil. Health professionals in endemic areas need to be aware of the clinical presentation and appropriate clinical management of the disease because early diagnosis and early initiation of antibiotic therapy can be life-saving.

Background

Melioidosis is an infectious and neglected disease caused by the bacteria Burkholderia pseudomallei, a Gram-negative bacillus that naturally inhabits soils and water that occurs predominantly in tropical regions [1,2,3]. It can infect humans or animals and is mainly transmitted through skin contact, mucous membranes, inhalation, or ingestion [4]. Vertical transmission, maternal milk transmission and sexual transmissions have also been reported [5, 6]. In Brazil, the disease was first recorded in 2003 in an outbreak in Ceará State, where three of the four patients with a severe form of the disease died [7]. Awareness regarding melioidosis is still low in Brazil, making the disease underreported [7]. Patients infected with B. pseudomallei may develop severe pneumonia and sepsis. Diabetes mellitus (DM), chronic lung and renal diseases are known risk factors [6] for occurrence of fatal cases of melioidosis if not promptly diagnosed and treated. In the absence of rapid intensive treatment, patients can develop severe pulmonary involvement, and urinary and skin infections, arthritis, osteomyelitis, and, less frequently, neuromelioidosis. Bacteremia occurs in 40–60% of cases, sometimes without an evident focus of infection, and septic shock with pneumonia occurs in 20% of cases [8]. We report the first case series of seven laboratory-confirmed cases of melioiosis in Piauí State, Brazil.

Case presentations

The cases are summarized in Table 1 and described below.

Table 1 Clinical and laboratorial findings of cases of meliodosis in Piauí State, Brazil

Case 1

A 50-year-old woman with a history of multiple sclerosis (MS) was admitted to hospital in February 2019 with pneumonia that progressed to respiratory failure. The patient was underwent tracheostomy, gastrostomy, and antibiotic therapy with piperacillin/tazobactam was started after collection of blood and urine samples for culture. The urine sample was positive for B. pseudomallei on culture. The antibiotic regiment was changed to ceftazidime and meropenem. She was discharged from the hospital in July 2019 after 139 days with feeding via gastrostomy and passage of urine via a urinary catheter; next to application of aforementioned antibiotics, the patient was treated with risperidone, lamotrigine, scopolamine, and omeprazole.

Case 2

An 80-year-old man with hypertension was admitted to hospital in February 2019 with a 3-month history of a petechial rash on the arms and abdomen, associated with pruritus. The patient was diagnosed with steroid refractory idiopathic thrombocytopenic purpura (ITP). His condition did not improve, and 2 weeks after admission he underwent a chest computed tomography (CT), which showed lesions suggestive of alveolar hemorrhage, requiring positive pressure ventilation and mechanical compression of the pulmonary vessels to reduce alveolar bleeding. Six weeks after admission, the patient developed fever (38.5 °C), abdominal pain, and dyspnea. Blood culture was positive for B. pseudomallei and the patient was treated with meropenem. However, he developed airway hemorrhage and cardiorespiratory arrest, resulting in the patient’s death the following day, 43 days after admission.

Case 3

A 22-year-old man with a history of systemic lupus erythematosus (SLE) and fibromyalgia was hospitalized on March 2019 due to abdominal pain and weakness in the legs. Magnetic resonance imaging revealed the presence of free fluid in the abdominal cavity and a pericardial effusion. Two weeks after admission, antibiotic therapy with meropenem was started and subsequently changed to sulfamethoxazole/trimethoprim (SMZ/TMP) after a positive blood culture for B. pseudomallei. The patient developed fever, intense pain in the right iliac fossa, and the right sacroiliac joint, which restricted walking. Pelvic magnetic resonance imaging showed an inflammation suggestive of osteomyelitis. Laborataroy analysis showed proteinuria (764.2 mg/24 h), and anti-nuclear antigen (ANA) positive (titer: 1:1280) and anti-DNA antibodies (titer: 1:40). The patient was diagnosed with class IV lupus nephritis. His condition deteriorated, with persistent fever (39.5 °C) associated with hypotension, and a decreased level of consciousness. He was admitted to the ICU and after 44 days of hospitalization, he was discharged and continued treatment with SMZ/TMP, hydroxychloroquine, and prednisone.

Case 4

A 63-year-old woman was admitted to hospital in October 2019 due to weakness, productive cough, and fever (38 °C), for 2 weeks. She was hypertensive, diabetic and had chronic renal disease with history of liver transplantation due to alcoholic cirrhosis and treatment for tuberculosis. The patient received a Blood transfusion and antibiotic therapy with ceftriaxone was started, but the patient developed acute respiratory failure. Chest CT showed pleural effusion on the right, compressive atelectasis of the adjacent alveolar parenchyma associated with ground-glass opacities in several lung fields. Blood culture was positive for B. pseudomallei. The patient was treated with meropenem and was discharged one month later.

Case 5

A 38-year-old woman with a history of DM was admitted to hospital in December 2020 with hypothyroidism, cough, fever, abdominal pain, and weight loss. Chest CT showed excavated lesions in the left lung with extensive homogeneous parenchymal opacities in the lower lobe and in the posterior segment of the upper lobe of the right lung. Bronchoscopy was performed, and the culture of the bronchoalveolar lavage fluid was positive for B. pseudomallei with sensitivity to SMZ/TMP, ceftazidime, and meropenem. The patient was discharged 33 days after admission and prescribed SMZ/TMP for a further 3 months.

Case 6

A 25-year-old diabetic patient was admitted to hospital in July 2021 with fever, asthenia, and pain in the right hypochondrium and right lumbar region that radiated to the right inguinal region, for 25 days. Reported pyelonephritis improved after cefepime and vancomycin. CT of the abdomen and chest showed three expansive lesions in the liver, compatible with liver abscesses and bilateral pleural effusion with compressive atelectasis of the underlying lung parenchyma. On 08/23/21, the patient underwent drainage of abscesses, and the culture of the sample was positive for B. pseudomallei. After treatment with meropenem the patient was discharged after 32 days of hospitalization.

Case 7

A 41-year-old man with a history of type 1 DM was admitted to hospital in October 2021 with fever (39 °C) for more than 1 month, chills, dry cough, pale feces, and dark urine. The patient had edema of the legs and chest CT showed a hypodense heterogeneous lesion in the right hepatic lobe, segments VIII and V, and splenomegaly. Empiric antibiotic therapy was started with ciprofloxacin and metronidazole. Blood culture was positive for B. pseudomallei and the antibiotic was switched to meropenem (Fig. 1). Abdominal CT confirmed the presence of free fluid in the upper abdomen and a bilateral pleural effusion. Culture of pus from the liver abscess was also positive for B. pseudomallei and this was confirmed by molecular analysis. The patient was discharged from hospital after 29 days.

Fig. 1

Left: Gram-negative bacilli of Burkholderia pseudomallei with characteristic hyperchromatic bipolar staining. Right: Burkholderia pseudomallei isolates on blood agar and MacConkey agar from liver abscess contents

Discussion

This is the first documented case series of patients diagnosed with melioidosis in Piauí State, Brazil. Three patients were females and four were males, with ages ranging from 22 to 80 years. All patients had comorbidities: DM (4 patients), SLE (1 patient), MS (1 patient), and ITP (1 patient). They presented different manifestations including pulmonary involvement, abscesses, and skin involvement, with a mortality rate of 14% (1/7). Other studies have reported fatality rates of 5.7%, 20.5%, and 32.2% [10, 11]. In addition to alcoholism [9], and DM [10], the most common risk factors associated with melioidosis are: (i) advanced age, (ii) exposure to soil and (iii) water contaminated with B. pseudomalle, mainly workers who carry out agricultural activities, and (iv) comorbidities such as chronic kidney and lung diseases, heart disease, and thalassemia [10]. We observed that the cases were not related to each other and the possible infection source of infection could not be determined in the study. In relation to clinical manifestations, the patients had in common: fever (6), cough (4), abdominal pain (4), dyspnea (2) and leg weakness (2).The results also showed a similar pattern, with most patients having a pre-existing metabolic disorder, which may have contributed to the clinical development of melidioidosis. Other case reports are presented in Table 2. Regarding the diagnosis, the bacterium was isolated from blood (Cases 2, 3, 4, and 7), urine (Case 1), bronchioalveolar lavage fluid (Case 5), and liver abscesses (Cases 6 and 7), and all samples were seeded in culture media specific for clinical specimens. After growth, the isolates were subjected to automated identification, however only four isolates were sent for molecular testing (Cases 4, 5, 6, and 7), most likely because of a lack of prior knowledge of melioidosis in this region, and the lack of established flows and protocols for the referral of patients with infectious diseases.

Table 2 Distribution of melioidosis cases reported between 2021 and 2022, according to melioidosis.info [12]

Conclusions

Melioidosis is an emerging and neglected disease in Brazil and its diagnosis needs to be investigated in patients with risk factors, such as DM and renal failure. It needs to be considered in the differential diagnosis of other diseases with a similar clinical picture, such as abscesses caused by M. tuberculosis, certain Salmonella enterica spp, and Treponema pallidum. Given the high prevalence of tuberculosis in Brazil, increased surveillance is necessary because these two diseases require different antibiotic treatment. This first cases series of melioidosis to be reported in Piauí State highlights the need to develop a structured network with a trained team and an adequate structure of the laboratories for the investigation and detection of B. pseudomallei infection, which has a high case fatality rate in the absence of timely and specific treatment.